| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Com...
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.1...